Trial results

Tirzepatide in MetALD

NCT07046819 on ClinicalTrials.gov · last registry update 2026-08-12

Recruiting now, toward 120 participants. Due to report 30 July 2027. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for alcohol use disorder — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

RECRUITING

Phase

P2

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Sponsor type

Nih

Enrollment

120

Started

2026-06-11

Primary completion

2027-07-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Metabolic improvement from baseline as measured by percentage reduction of body weight and reduction in liver steatosis from baseline as measured by percentage reduction in Fibroscan controlled attenuation parameter (CAP) score.

Conditions studied

Metabolic Alcohol-associated Liver Disease · Alcohol Use Disorder

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.